Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.

Arthritis Rheumatol · 2019 · PMC6593802 · PMID 30427585

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients receiving tofacitinib with a confirmed nadir ALC of <500 cells/mm 3 had an increased risk of serious infection, while herpes zoster showed a trend toward an increasing risk with lower ALC values.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.